User profiles for N. Aikawa
 | Nadia Emi AikawaMédica Assistente da Disciplina de Reumatologia, Universidade de Sao Paulo Verified email at hc.fm.usp.br Cited by 4192 |
Neutrophil-mediated tissue injury and its modulation
S Fujishima, N Aikawa - Intensive care medicine, 1995 - Springer
Neutrophils play a key role in the development of the systemic inflammatory response syndrome
(SIRS) and multiple organ dysfunction syndrome (MODS). Since the lungs are the main …
(SIRS) and multiple organ dysfunction syndrome (MODS). Since the lungs are the main …
Autoimmune primary ovarian insufficiency
Primary ovarian insufficiency (POI) is defined as sustained amenorrhea, increased follicle-stimulating
hormone and low estrogen levels, whereas diminished ovarian reserve (DOR) is …
hormone and low estrogen levels, whereas diminished ovarian reserve (DOR) is …
Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome
N Aikawa, Y Kawasaki - Therapeutics and clinical risk …, 2014 - Taylor & Francis
… sivelestat group (n=18) and a historical control group (n=25) … pneumonia (sivelestat group,
n=23; control group, n=21) was … patients (sivelestat group, n=34; control group, n=15) with ALI…
n=23; control group, n=21) was … patients (sivelestat group, n=34; control group, n=15) with ALI…
[HTML][HTML] Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized …
…, S Shimazaki, Y Yamamoto, N Aikawa… - Journal of Thrombosis …, 2007 - Elsevier
Background: Soluble thrombomodulin is a promising therapeutic natural anticoagulant that
is comparable to antithrombin, tissue factor pathway inhibitor and activated protein C. …
is comparable to antithrombin, tissue factor pathway inhibitor and activated protein C. …
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial
…, E Cordasco, CS Chang, S Oeyen, N Aikawa… - Jama, 2013 - jamanetwork.com
… Dr Aikawa reports being a medical advisor for the eritoran phase 3 clinical trial sponsored
by the Eisai Co. Dr Aikawa reports receipt of travel expenses from Eisai Inc. Dr Schein reports …
by the Eisai Co. Dr Aikawa reports receipt of travel expenses from Eisai Inc. Dr Schein reports …
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis
…, N Aikawa, I Demeyer, S Sainati, N Amlot… - Critical care …, 2010 - journals.lww.com
… A nonsignificant reduction in mortality rate was observed in a subset of patients with both
shock and respiratory failure (placebo [n= 51], 33%, vs. high dose [n= 52], 19%, p=. 10). …
shock and respiratory failure (placebo [n= 51], 33%, vs. high dose [n= 52], 19%, p=. 10). …
[HTML][HTML] Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
AC Medeiros-Ribeiro, NE Aikawa, CGS Saad… - Nature medicine, 2021 - nature.com
… <4 weeks before D0 (n = 24); demyelinating disease (n = 1); … (n = 25); inactivated virus
vaccine up to 2 weeks before D0 (n … study (n = 161); and hospitalization for general reasons (n = …
vaccine up to 2 weeks before D0 (n … study (n = 161); and hospitalization for general reasons (n = …
Photoluminescence and photocatalytic activity of highly dispersed titanium oxide anchored onto porous Vycor glass
M Anpo, N Aikawa, Y Kubokawa, M Che… - The Journal of …, 1985 - ACS Publications
Conclusions The results presented here suggest that a transition-metal surface can be a
reagent in redox and acid-base reactions. A clean tungsten surface was an extremely strong …
reagent in redox and acid-base reactions. A clean tungsten surface was an extremely strong …
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in …
…, D Ernest, SP LaRosa, J Pachl, N Aikawa… - Critical care …, 2013 - journals.lww.com
… Aikawa received consultation fees from Asahi-Kasei for the Japanese P-3 and P-4 studies
and expenses from Artisan Pharma for attending PAB meeting in July 17, 2009. Dr. Levy is a …
and expenses from Artisan Pharma for attending PAB meeting in July 17, 2009. Dr. Levy is a …
An historical overview of the preparation of the UNESCO International Convention for the Safeguarding of the Intangible Cultural Heritage
N Aikawa - Museum international, 2004 - Taylor & Francis
UNESCO travelled a long road before finally securing, in 2003 and without a dissenting vote,
1 the adoption of an International Convention for the Safeguarding of the Intangible …
1 the adoption of an International Convention for the Safeguarding of the Intangible …